BioMarin Pharmaceutical (NASDAQ:BMRN) Earns Outperform Rating from Analysts at BMO Capital Markets

BMO Capital Markets initiated coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN) in a research note published on Wednesday, Marketbeat reports. The firm issued an outperform rating and a $98.00 price objective on the biotechnology company’s stock.

BMRN has been the subject of a number of other reports. Sanford C. Bernstein reduced their price target on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Canaccord Genuity Group increased their price objective on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Citigroup boosted their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Weiss Ratings lowered BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright lowered their price target on BioMarin Pharmaceutical from $60.00 to $59.00 and set a “neutral” rating on the stock in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $88.83.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $66.70 on Wednesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The stock has a market cap of $12.91 billion, a PE ratio of 180.27, a price-to-earnings-growth ratio of 0.48 and a beta of 0.24. The stock has a fifty day moving average of $60.67 and a 200-day moving average of $57.88.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. BioMarin Pharmaceutical’s revenue was up 20.0% compared to the same quarter last year. During the same period last year, the business earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts anticipate that BioMarin Pharmaceutical will post 4.11 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Activest Wealth Management bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $26,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at about $39,000. CIBC Private Wealth Group LLC boosted its holdings in BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 179 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in BioMarin Pharmaceutical during the 3rd quarter valued at about $40,000. Finally, Parallel Advisors LLC grew its position in BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 295 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.